MedTrace Logo

PGD2 Formation in Vascular Injury

NCT01001260 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 51

Last updated 2019-06-11

No results posted yet for this study

Summary

To investigate the biosynthesis of PGD2 during percutaneous transluminal coronary angioplasty (PTCA) procedure.

Conditions

Interventions

DRUG

No ASA

Alternative antiplatelet therapy instead of aspirin

DRUG

Low dose ASA

Low dose aspirin (81mg) prior to PTCA

DRUG

325 mg ASA

high dose of aspirin prior to PTCA

Sponsors & Collaborators

Principal Investigators

  • Garret FitzGerald, MD · University of Pennsylvania

  • Wenliang Song, MD · University of Pennsylvania

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2011-02-28
Completion
2012-01-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01001260 on ClinicalTrials.gov